RxDoctor Payments Data

Robert Barkett, MD

Internal Medicine · Mansfield, OHNPI 1346310174

Payments from drug & device makers

$18,379in general payments, 2019–2025

Across 1,171 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Bayer$1K
  • plus $10K from 50 others

What the payments were for

  • Food & beverage$18,17899%
  • Education$2021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk167$1,783
Lilly USA, LLC133$1,712
Amgen52$1,363
AstraZeneca45$1,269
Pfizer107$1,123
Bayer91$1,106
Merck61$948
Johnson & Johnson70$942
Axsome Therapeutics, Inc.26$760
GSK51$749
Boehringer Ingelheim52$727
Xeris Pharmaceuticals, Inc.32$519
Corcept Therapeutics30$502
Esperion Therapeutics, Inc.22$476
Sanofi-aventis U.S. LLC24$434
AbbVie16$403
Astellas Pharma US Inc17$349
Novartis27$309
Takeda Pharmaceuticals U.S.A., Inc.17$248
Medtronic3$225
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$209
Otsuka America Pharmaceutical, Inc.5$175
Amarin Pharma, Inc.12$172
Exact Sciences9$171
Idorsia Pharmaceuticals US Inc9$163
Arbor Pharmaceuticals, Inc.10$151
Abbott1$139
Optinose US, Inc.3$133
Azurity Pharmaceuticals, Inc.8$130
E.r. Squibb & Sons, L.L.C.4$114
Phathom Pharmaceuticals, Inc.6$109
Lundbeck LLC6$106
Eisai Inc.6$106
Biohaven Pharmaceuticals, Inc.5$75
Mylan Specialty L.p.3$54
Edwards Lifesciences2$37
Hikma Pharmaceuticals USA2$34
Biohaven Pharmaceutical Holding Company Ltd.2$31
Zyla Life Sciences, Inc.2$30
Circassia Inc.2$27
Shield Therapeutics Inc1$23
Actelion Pharmaceuticals US, Inc.1$23
Verona Pharma, Inc.1$22
Eyevance Pharmaceuticals LLC1$20
GRT US Holding, Inc.1$19
Teva Pharmaceuticals USA, Inc.1$17
Jazz Pharmaceuticals Inc.1$17
Verity Pharmaceuticals Inc.1$17
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Antares Pharma, Inc.1$16
Regeneron Healthcare Solutions, Inc.1$14
Shire North American Group Inc1$14
Avanir Pharmaceuticals, Inc.1$13
Assertio Therapeutics, Inc.1$13
Currax Pharmaceuticals LLC1$12
Travere Therapeutics, Inc.3$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,379 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$193,942
Medicare patients
457
Services billed
3,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$269,185
TrulicityDulaglutide136$193,282
Trelegy ElliptaFluticasone/Umeclidin/Vilanter179$151,222
XareltoRivaroxaban109$113,667
SynjardyEmpagliflozin/Metformin Hcl80$102,538
OzempicSemaglutide81$99,543
KerendiaFinerenone77$77,679
Tresiba Flextouch U-200Insulin Degludec86$75,629
JardianceEmpagliflozin87$75,184
FarxigaDapagliflozin Propanediol70$72,546
MounjaroTirzepatide48$54,753
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog84$49,373
Soliqua 100-33Insulin Glargine/Lixisenatide30$45,401
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog65$45,119
Repatha SureclickEvolocumab51$40,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,123$269,185291 claims
Lilly USA, LLCTrulicity, Mounjaro$1,712$248,035184 claims
Boehringer IngelheimSynjardy, Jardiance, Synjardy Xr$727$205,347201 claims
GSKTrelegy Ellipta, Breo Ellipta$749$176,945220 claims
Johnson & JohnsonXarelto, Invokamet$942$140,588125 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,269$105,259118 claims
Novo NordiskOzempic$1,783$99,54381 claims
BayerKerendia$1,106$77,67977 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$434$45,40130 claims
AbbVieCreon, Fetzima$403$40,49524 claims
NovartisEntresto$309$34,76536 claims
AmgenProlia$1,363$33,21320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →